CA2308873C - Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides - Google Patents

Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides Download PDF

Info

Publication number
CA2308873C
CA2308873C CA002308873A CA2308873A CA2308873C CA 2308873 C CA2308873 C CA 2308873C CA 002308873 A CA002308873 A CA 002308873A CA 2308873 A CA2308873 A CA 2308873A CA 2308873 C CA2308873 C CA 2308873C
Authority
CA
Canada
Prior art keywords
composition
calcium
inhibitor
use according
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002308873A
Other languages
English (en)
French (fr)
Other versions
CA2308873A1 (fr
Inventor
Lionel Breton
Isabelle Nonotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9545714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2308873(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Publication of CA2308873A1 publication Critical patent/CA2308873A1/fr
Application granted granted Critical
Publication of CA2308873C publication Critical patent/CA2308873C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002308873A 1999-05-18 2000-05-11 Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides Expired - Fee Related CA2308873C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906290A FR2793681B1 (fr) 1999-05-18 1999-05-18 Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
FR9906290 1999-05-18

Publications (2)

Publication Number Publication Date
CA2308873A1 CA2308873A1 (fr) 2000-11-18
CA2308873C true CA2308873C (fr) 2006-11-14

Family

ID=9545714

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308873A Expired - Fee Related CA2308873C (fr) 1999-05-18 2000-05-11 Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides

Country Status (8)

Country Link
US (2) US6344461B1 (enExample)
EP (1) EP1053745B2 (enExample)
JP (2) JP2000351736A (enExample)
AT (1) ATE335525T1 (enExample)
CA (1) CA2308873C (enExample)
DE (1) DE60029866T3 (enExample)
ES (1) ES2269075T5 (enExample)
FR (1) FR2793681B1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793681B1 (fr) * 1999-05-18 2001-06-22 Oreal Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
FR2826267B1 (fr) 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un agent myorelaxant
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
FR2846882A1 (fr) * 2002-09-05 2004-05-14 Oreal Utilisation d'une amine phenylee secondaire ou tertiaire pour lisser les rides et ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
FR2847469B1 (fr) * 2002-11-26 2006-04-07 Oreal Utilisation de l'adenosine ou d'un analogue d'adenosine, pour lisser les rides d'expression
US20040146474A1 (en) * 2002-11-26 2004-07-29 L'oreal Method for softening lines and relaxing the skin with adenosine and adenosine analogues
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
US20040244062A1 (en) * 2003-06-02 2004-12-02 Crittenden Jill R. Use of protein inhibitors as antithrombotic agents
US20050008607A1 (en) * 2003-06-05 2005-01-13 L'oreal Composition containing a carbonyl amine
US20050080076A1 (en) * 2003-10-08 2005-04-14 Xanodyne Pharmacal, Inc. N-desmethyl levomepromazine
FR2866810B1 (fr) * 2004-03-01 2006-04-28 Oreal Utilisation d'au moins un inhibiteur des canaux calciques pour prevenir et/ou traiter la peau grasse.
FR2869902B1 (fr) * 2004-05-06 2008-01-25 Oreal Composition, notamment cosmetique, comprenant un ester de ((dialkylamino)alcoxy) ethanol
FR2871462B1 (fr) * 2004-06-15 2006-11-17 Oreal Nouveaux derives de piperidine et utilisation cosmetique
ATE455762T1 (de) * 2004-06-15 2010-02-15 Oreal Verwendung von piperidinderivaten in der kosmetik
FR2872416B1 (fr) 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
CA2588131C (en) * 2004-12-22 2014-02-11 Avon Products, Inc. Method and composition for reducing the appearance of wrinkles
FR2884712B1 (fr) * 2005-04-21 2007-06-15 Oreal Compositions cosmetiques comprenant des derives de piperazine
US20070048243A1 (en) * 2005-08-30 2007-03-01 L'oreal Anti-aging composition containing criste marine and padina pavonica extracts
US20070071840A1 (en) * 2005-09-27 2007-03-29 Sridevi Dhanaraj Method for treatment of cartilage disorders with centella extract
FR2903901B1 (fr) * 2006-07-21 2009-02-27 Oreal Utilisation de composes antagonistes des canaux calcium pour depigmenter la peau.
WO2008009860A2 (fr) * 2006-07-21 2008-01-24 L'oreal Utilisation de composés antagonistes des canaux calcium pour dépigmenter la peau
ITRM20060440A1 (it) * 2006-08-10 2008-02-11 Carmine Antropoli Uso della nifedipina per il trattamento antirughe
WO2008114082A1 (en) * 2007-03-21 2008-09-25 Dorr Felt Tippens Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or ageing skin, and/or hair loss
BRPI0801368A8 (pt) * 2008-05-12 2021-03-23 Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp processos de estabilização de radicais cátion de compostos fenotiazínicos, formulações cosmecêuticas, usos de compostos fenotiazínicos na preparação de formulações cosmecêuticas e métodos de prevenção de doenças e distúrbios de pele
WO2009152205A1 (en) * 2008-06-10 2009-12-17 Meta Cosmetics, Llc. Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
WO2010029554A1 (en) * 2008-09-11 2010-03-18 I.B.R. Israeli Biotechnology Research Ltd. Leucojum bulb extracts and use thereof
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
CA2642508C (en) * 2008-10-31 2011-10-04 Kenneth W. Adams Method of removal of hyperplastic skin lesions
IT1393416B1 (it) 2009-02-23 2012-04-20 Antropoli Composizioni a base di nifedipina per trattamenti antirughe
EP2467477B1 (en) 2009-08-17 2014-05-07 East Carolina University Fast acting snare-cleaving enzymes
CA2768653C (en) * 2009-08-31 2019-03-05 Avon Products, Inc. Cosmetic uses of modified stressed yeast extracts and related compositions
FR2953716B1 (fr) 2009-12-16 2015-03-27 Oreal Kit de formulation d'un produit cosmetique
JP2017528505A (ja) 2014-09-25 2017-09-28 ザ・ホスピタル・フォー・シック・チルドレンＴｈｅ Ｈｏｓｐｉｔａｌ Ｆｏｒ Ｓｉｃｋ Ｃｈｉｌｄｒｅｎ 発毛増進、皮膚再生促進及び創傷治癒のための組成物及び方法
FR3061002B1 (fr) 2016-12-23 2019-05-24 L'oreal Composition comprenant de l’acide hydroxyethylpiperazine ethane sulfonique et au moins un alkylpolyglucoside
CN108888594B (zh) * 2018-07-27 2021-07-23 广州柏赛罗药业有限公司 静脉注射给药的纳米脂肪乳剂
NL2035417B9 (en) 2022-07-19 2024-10-09 Coty Inc Cosmetic composition
NL2035921B1 (en) 2023-05-05 2025-01-27 Coty Inc Cosmetic composition
WO2025137552A1 (en) 2023-12-22 2025-06-26 Coty Inc. Cosmetic compositions comprising a lotus flower extract blend and method for reducing facial sweat

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322007A (ja) * 1986-03-26 1988-01-29 Kanebo Ltd 皮膚化粧料
JPS62270519A (ja) * 1986-05-20 1987-11-24 Kanebo Ltd 養毛化粧料
LU87068A1 (fr) * 1987-12-09 1989-07-07 Oreal Association a base de derives de pyrimidine et d'antagonistes de calcium en vue d'induire et de stimuler la croissance des cheveux et diminuer leur chute
JPH01238509A (ja) † 1988-03-16 1989-09-22 Shiseido Co Ltd 皮膚外用剤
US5612347A (en) * 1988-03-28 1997-03-18 Janssen Pharmaceutica N.V. Agents for preserving or restoring the soundness of the skin
BE1003002A6 (fr) * 1989-03-21 1991-10-22 Coppe Jan Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci.
US5214041A (en) * 1989-06-12 1993-05-25 Shiseido Company Ltd. Hair revitalizing tonic composition
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
DE3940315A1 (de) † 1989-12-06 1991-06-13 Speranta Dr Med Stratulat Muskelrelaxans, insbesondere fuer die gynaekologie
DE59002748D1 (de) † 1990-01-29 1993-10-21 Wogepharm Gmbh Verfahren zur Herstellung von Mitteln zur Therapie von Hauterkrankungen.
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
JPH04275217A (ja) * 1991-03-01 1992-09-30 Nikko Kyodo Co Ltd 経皮吸収型製剤
WO1992018116A1 (en) † 1991-04-10 1992-10-29 Yu Ruey J Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
AU4543193A (en) * 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
JPH09500869A (ja) † 1993-05-14 1997-01-28 エス． アーノン，スティーブン トキシンの治療的使用に対する副作用および非感受性を防ぐ方法
JPH07131217A (ja) * 1993-11-08 1995-05-19 Kyocera Corp 誘電体共振器
US5554608A (en) * 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
ATE228834T1 (de) * 1994-09-30 2002-12-15 Oreal Verwendung von einem agonisten eines mit einem chloridkanal assozierten rezeptors zur behandlung von hautfalten
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
AU1058797A (en) * 1995-11-22 1997-06-11 Bristol-Myers Squibb Company Treatment with calcium channel blockers for drug-induced hypersensitivity
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2746641B1 (fr) * 1996-03-27 1998-06-05 Oreal Utilisation d'un extrait d'au moins une iridacee dans le traitement des rides
US6497890B2 (en) * 1996-12-03 2002-12-24 Parvin Youssefyeh Anti-wrinkle preparation and method of reducing wrinkles in facial skin and neck
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid
FR2777186B1 (fr) * 1998-04-10 2001-03-09 Oreal Utilisation d'au moins un hydroxystilbene dans une composition raffermissante
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
EP1158919B1 (en) * 1999-03-09 2005-06-29 Thermage, Inc. Apparatus for treatment of tissue
FR2793681B1 (fr) * 1999-05-18 2001-06-22 Oreal Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
FR2798590B1 (fr) * 1999-09-21 2001-11-30 Oreal Utilisation de l'alverine pour diminuer les rides

Also Published As

Publication number Publication date
FR2793681A1 (fr) 2000-11-24
JP2000351736A (ja) 2000-12-19
CA2308873A1 (fr) 2000-11-18
US6908925B2 (en) 2005-06-21
DE60029866T3 (de) 2010-11-25
EP1053745A1 (fr) 2000-11-22
FR2793681B1 (fr) 2001-06-22
ATE335525T1 (de) 2006-09-15
ES2269075T3 (es) 2007-04-01
US6344461B1 (en) 2002-02-05
US20020058682A1 (en) 2002-05-16
EP1053745B1 (fr) 2006-08-09
EP1053745B2 (fr) 2010-04-28
ES2269075T5 (es) 2010-08-23
DE60029866T2 (de) 2007-01-18
DE60029866D1 (de) 2006-09-21
JP2006131645A (ja) 2006-05-25

Similar Documents

Publication Publication Date Title
CA2308873C (fr) Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
EP0704210B1 (fr) Utilisation d'une substance agoniste d'un récepteur associé à un canal chlore dans le traitement des rides
CA2148652C (fr) Utilisation d'un antagoniste de substance p dans une composition cosmetique et composition obtenue
FR2798590A1 (fr) Utilisation de l'alverine pour diminuer les rides
EP0756862B1 (fr) Utilisation d'un antagoniste de bradykinine dans une composition cosmétique, pharmaceutique ou dermatologique et composition obtenue
FR2728793A1 (fr) Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR2812190A1 (fr) Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2751537A1 (fr) Utilisation du miel comme agent keratolytique, notamment pour ameliorer l'eclat du teint de la peau et traiter les rides
CA2348102A1 (fr) Utilisation du manganese dans le traitement des rides
EP1837013B1 (fr) Composition comprenant de l'hydroxyapatite et un sel de calcium pour renforcer la fonction barrière de la peau et/ou des semi-muqueuses.
CA2245206C (fr) Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2812192A1 (fr) Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2816837A1 (fr) Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau
FR2738485A1 (fr) Utilisation d'au moins un extrait d'au moins une bacterie filamenteuse non photosynthetique en tant qu'antagoniste de substance p
FR2758263A1 (fr) Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2968952A1 (fr) Ester d'acide amine n-acyle a titre d'agent apaisant
EP1155685B1 (fr) Composition comprenant du manganèse
FR2868952A1 (fr) Nouvelle composition a base d'uree et ses applications dans les domaines cosmetiques ou dermatologiques
FR2877565A1 (fr) Utilisation d'un sulfate de dextran de haut poids moleculaire comme agent apaisant
FR2818131A1 (fr) Composition cosmetique comprenant de l'heparanase
FR2719476A1 (fr) Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
WO2001082929A2 (fr) Epichatechine comme inhibiteur de no-synthase et utilisations
FR2826268A1 (fr) Utilisation de tyrosine sulfatee dans une composition destinee a traiter les manifestations cutanees du vieillissement

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed